Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The AB7 Trial: Atezolizumab and Bevacizumab in Child-Pugh B7/B8 HCC
NCT04829383Phase 2Completed
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC). Primary endpoint: Grade 3-5 Adverse Events at 10 months. Started Mar 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04829383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829383.